Trials / Withdrawn
WithdrawnNCT00789165
Empiric Quinidine for Asymptomatic Brugada Syndrome
A Prospective Trial Of Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome.
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- International Registry of Asymptomatic Brugada Syndrome · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if quinidine therapy (not guided by the results of electrophysiologic studies) will reduce the long-term risk of arrhythmic events in asymptomatic Brugada Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | quinidine | quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily. |
| DRUG | no therapy | No therapy; this is not a placebo-controlled trial |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2020-02-01
- Completion
- 2020-12-31
- First posted
- 2008-11-11
- Last updated
- 2020-02-13
Locations
6 sites across 6 countries: United States, Germany, Israel, Italy, Japan, Netherlands
Source: ClinicalTrials.gov record NCT00789165. Inclusion in this directory is not an endorsement.